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1. Introduction 
GABA may well be a major inhibitory transmitter 
in the mammalian CNS [l] and agents which inhibit 
its synthesising enzyme glutamate decarboxylase 
usually lower brain GABA levels and cause seizures 
[ 21. Conversely, agents which raise brain GABA levels 
usually protect against convulsions. The latter com- 
pounds may well act by inhibiting the GABA degrading 
enzymes GABAT and SSAD. One such agent is sodium 
n-dipropyl acetate, the salt of an 8-carbon branched 
fatty acid, which is a recently introduced clinical 
anticonvulsant [3]. It has been shown to produce a 
30-40% elevation of total brain GABA following a 
single intraperitoneal injection into mice, and the 
time of peak elevation of GABA corresponds to the 
time of maximum protection against seizures [4]. 
Following the extraction of brain GABAT and its 
assay in the presence of dPA, these authors have 
concluded that the rise in GABA concentration 
results from the inhibition of this enzyme. However, 
since the metabolic route of GABA degradation 
involves two enzymes, namely GABAT and SSAD, 
the possibility arises that more than one enzyme is 
inhibited by dPA. This paper reports an inhibition 
of SSAD by dPA which appears to be more potent 
than its action on GABAT. 
Abbreviations: dPA: Sodium n - dipropylacetate; GABA: 
y-amino butyric acid; GABAT: 4 amino-butyrate 2-oxogluta- 
rate transminase (EC 2.6.1.19); SSA: Succinic semialdehyde: 
SSAD; Succinic semialdehyde dehydrogenase; OAAA: oxy- 
aminoacetic acid. 
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2. Materials and methods 
2.1. SSAD and SSA preparation and assay 
SSAD was prepared from guinea pig kidney accord- 
ing to the method of Pitts et al. [5], and from rat brain 
by the method of Kammeraat and Velstra [6] . SSA was 
prepared by the method of Langheld [7] as modified 
by Bruce et al. [8] . A higher yield was obtained if 
the sodium hypochlorite and sodium glutamate were 
incubated for 60 min as opposed to the original 10 
to 15 min. SSAD was assayed by the method of 
Kammaraat [6], the rate of reduction of NAD being 
followed fluorimetrically. The SSA preparations were 
assayed against standard NADH by employing SSAD. 
212. GABATpreparation and assay 
Partially purified GABAT was prepared from rat 
brain by Fowler’s method [9], except that Triton 
X-l 00 was omitted from the initial homogenising 
medium as it interfered with the subsequent assay. 
Maximal activation of the enzyme was obtained 
instead by exposing the crude homogenate to ultra- 
sound (15 kI-Iz; 8 /.J amplitude; stainless steel probe) 
for six bursts of 30 set with cooling for 3 min between 
each exposure. The enzyme was assayed by the method 
of Balazs et al. [ lo] . This employs the transamination 
of SSA with glutamate to produce GABA, and the 2- 
oxoglutarate generated is reduced by glutamate dehydro- 
genase in the presence of excess ammonium ion. As 
the SSA preparation contained 2-oxoglutarate as an 
impurity, the reaction mixture was preincubated, in 
the absence of GABAT, and with excess NADPH 
(0.16 mM) for 10 min at room temperature to convert 
this 2-oxoglutarate to glutamate before starting the 
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Fig.1. Regression lines for Lineweaver-Burk plots for SSAD: (0) SSA alone; (a) in the presence of 5 mM dPA; (A) in the 
presence of 10 mM dPA. V is in arbitrary fluorometric units. Each point is the mean of between 6 and 10 experiments. A)Rat 
brain SSAD. SSA concentrations: 4 X 10e6 M-5 X lo-’ M. K, (apparent) for SSA is 1 X lo-’ M. B) Guinea pig kidney 
SSAD. SSA concentrations: 6 X lo-‘M-5 X lo-’ M. K,,, (apparent) for SSA 8.6 X lo-’ M. 
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Fig.2. Determination of approximate Ki for inhibition of 
SSAD by dPA. V is in arbitrary fluorometric units, dPA 
concentrations in mM. A) Rat brain SSAD. SSA concen- 
trations: (0) 4 X 10e6 M, (m) 2 X 10e6 M, (A) 1 X lo-’ M. 
Ki is approximately 1.5 X lo- 'M. B) Guinea pig kidney 
SSAD. SSA concentrations: (0) 1.7 X 10ms M, (e) 1.3 X 10e5 M, SSA is chemically measured, and not assayed enzy 
(A) 0.8 X lo-’ M, (7) 0.7 X lo-’ M. Ki is approximately mically employing SSAD. Although these analogues 
0.5 x 10-s M. were effective inhibitors of GABAT, the data given 
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assay by addition of GABAT. The GABAT preparation 
showed no SSAD activity and was totally inhibited 
by 1 X IO-’ M OAAA, a specific inhibitor of 
GABAT [9]. Glutamate dehydrogenase was not 
inhibited by dPA. 
3. Results 
3.1. SSAD inhibition 
Conventional Lineweaver-Burk plots of k against f
produced on apparent K, of 1 .O X lo-’ M for brain 
SSAD, and 8.6 X 10m6 for the kidney enzyme (fig.1). 
Both were substantially and significantly inhibited by 
dPA (5 and 10 mM), with an apparent Ki of approxi- 
mately 1.5 X 10m3 for brain and 0.5 X 10e3 M for 
kidney. 
3.2. GABA T activity 
The GABAT extracted from brain displayed an 
apparent Km of 6 X 10m3 M. Although the data of 
fig.3 suggest an apparently competitive inhibition of 
GABAT by dPA with respect to SSA, and a non- 
competitive inhibition with respect to glutamate, 
analysis shows that there is no significant difference 
between the respective regression lines. It appears, 
therefore, that dPA is having little or no effect on 
the activity of this enzyme. 
4. Discussion 
The above results demonstrate that SSAD from 
rat brain and from guinea pig kidney is more potently 
inhibited by dPA than is GABAT from rat brain. It 
is therefore probable that SSAD provides the pri- 
mary site of action of dPA in the GABA shunt path- 
way of brain. The effect of dPA on GABAT reported 
by Simler et al. [4] is probably due to an effect on 
SSAD; which, although initially present in their assay 
in excess, could have become rate-limiting following its 
inhibition by dPA. Maitre et al. [ 1 l] , from the same 
laboratory, have examined the inhibition of GABAT 
by two analogues of dPA using a technique in which 
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Fig.3. Regression lines for Lineweaver-Burk plots for GABAT. Each point is the mean of at least six experiments. A) SSA. 
1.7 x lo-’ M. (0) Glutamate 20 X low3 M-2.5 X 1Om3 M, (=I with 10 mM dPA. The difference between the two regression 
tines is not significant (P>O.OS). B) Glutamate 10 X 10m3 M. (0) SSA 1.7 X 10e3 M-O.34 X 10e3 M, (9) with 10 mM 
dPA. Difference between two regression lines is not significant. (P>O.l). 
for dPA suggests a Kj value of 18 X 10m3 M. 
The coincidence of peak GABA levels with the 
maximum anticonvulsant effect of dPA suggests a 
direct causal link between the two. However, raised 
intracellular GABA concentration will not necessarily 
lead to raised GABA levels at inhibitory receptors, 
and demonstrating a changed compartmentation of 
GABA in favour of an extracellular location is likely 
to be of more significance in the mode of action 
of dPA. 
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